



Clinical trial results:

VERSATIS - Efficacité et tolérance d'emplâtres de lidocaïne à 5% (Versatis® 5%) dans les douleurs neuropathiques et dans les douleurs de crises vaso-occlusives drépanocytaires de l'enfant, de l'adolescent et du jeune adulte

VERSATIS - Lidocaïne 5% plasters (Versatis® 5%) in pediatric neuropathic pains and vasoocclusive sickle cell crisis pain

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2010-023461-22 |
| Trial protocol | FR |
| Global end of trial date | 27 March 2014 |

Results information

| | |
|-----------------------------------|---|
| Result version number | v1 (current) |
| This version publication date | 13 March 2021 |
| First version publication date | 13 March 2021 |
| Summary attachment (see zip file) | Publication Versatis (VERSATIS_ROUSSEAU et al_Accepted article.pdf) |

Trial information

Trial identification

| | |
|-----------------------|------------|
| Sponsor protocol code | ET2010-077 |
|-----------------------|------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01314300 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Centre Léon Bérard |
| Sponsor organisation address | 28 rue Laennec, LYON, France, 69008 |
| Public contact | Centre Léon Bérard, Centre Léon Bérard, 33 478782968, DRCIreglementaire@lyon.unicancer.fr |
| Scientific contact | Dr Perrine MAREC-BERARD, Dr Perrine MAREC-BERARD, 33 478782828, DRCIreglementaire@lyon.unicancer.fr |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 15 December 2014 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 26 March 2014 |
| Global end of trial reached? | Yes |
| Global end of trial date | 27 March 2014 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Estimer l'efficacité à 12 heures de Versatis® 5% sur la réduction des douleurs neuropathiques pures ou mixtes et sur la réduction des douleurs de crises vaso-occlusives drépanocytaires, localisées, superficielles, chez l'enfant, l'adolescent et le jeune adulte

Proportion of patients with a significant pain score decrease i.e. difference in VAS pain score of at least two points between t0 and t12 (12h-VAS \geq 2p-decrease) during at least two out of the three consecutive days of treatment.

Protection of trial subjects:

Within the framework of this study, the patients included will be followed according to the recommendations for the management of pain. The pain score was assessed by a 100 mm-Visual Analogue Score (VAS) self-assessment graduated from 0 (no pain) to 10 (maximal pain) at patch application (t0), at 6 hours (t6), and at 12 hours (t12) post application during three consecutive days. The analgesic treatments prescribed before the inclusion was not changed during the three days of evaluation unless absolutely required. In case of significant increase in pain during the three days (i.e. at least two points increasing in VAS score), the use of additional level II or level III analgesics, antiepileptics, or antidepressants was allowed and collected.

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 05 July 2011 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | France: 39 |
| Worldwide total number of subjects | 39 |
| EEA total number of subjects | 39 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

| | |
|--|----|
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 13 |
| Adolescents (12-17 years) | 13 |
| Adults (18-64 years) | 13 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

France

1st inclusion : 05/07/2011

Last patient last visit : 27/03/2014

Pre-assignment

Screening details:

Children and young adults aged from 6 to 21 years old suffering from either neuropathic pain in an oncologic setting, or localized and superficial pain due to vaso-occlusive bone crises in sickle-cell patients, insufficiently relieved by the commonly used treatments were eligible. The DN4 score had to be ≥ 4 .

Period 1

| | |
|------------------------------|-----------------------------|
| Period 1 title | Treatment (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|-----------|--------------|
| Arm title | Experimental |
|-----------|--------------|

Arm description:

Efficacy of lidocaine 5% plaster

Treatment of pain by lidocaine 5% plaster

| | |
|--|----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Lidocaïne 5% plaster |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cutaneous patch |
| Routes of administration | Cutaneous use |

Dosage and administration details:

The lidocaine 5% patches (Versatis®, Grünenthal GmbH, Aachen, Germany) for cutaneous application consists of a hydrogel base stuck to a polyethylene terephthalate support covered with a protective film of polyethylene terephthalate.²² Each plaster, supplied in 10 by 14cm size and containing 700 mg of lidocaine, was applied to the painful area (the most painful one in case of several painful areas) for 12 hours per day (12 hours application then 12 hours without patch), and for at least three consecutive days. The patch was applied on intact skin, not irritated, not injured, to more thoroughly cover the painful area with the number of patches defined according to the size of the painful area and the patient's body surface

| | |
|---------------------------------------|--------------|
| Number of subjects in period 1 | Experimental |
| Started | 39 |
| Completed | 39 |

Baseline characteristics

Reporting groups

| Reporting group title | Treatment |
|--------------------------------|-----------|
| Reporting group description: - | |

| Reporting group values | Treatment | Total | |
|--|-----------|-------|--|
| Number of subjects | 39 | 39 | |
| Age categorical | | | |
| The mean age was 12.7 ±3.5 years | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 19 | 19 | |
| Adolescents (12-17 years) | 20 | 20 | |
| Adults (18-64 years) | 0 | 0 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| The mean age was 12.7 ±3.5 years | | | |
| Units: years | | | |
| arithmetic mean | 12.7 | | |
| standard deviation | ± 3.5 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 21 | 21 | |
| Male | 18 | 18 | |

End points

End points reporting groups

| | |
|---|--------------|
| Reporting group title | Experimental |
| Reporting group description: | |
| Efficacy of lidocaine 5% plaster | |
| Treatment of pain by lidocaine 5% plaster | |

Primary: Pain score

| | |
|---|---------------------------|
| End point title | Pain score ^[1] |
| End point description: | |
| Proportion of patients with a significant pain score decrease i.e. difference in VAS pain score of at least two points between t0 and t12 (12h-VAS \geq 2p-decrease) during at least two out of the three consecutive days of treatment | |
| End point type | Primary |
| End point timeframe: | |
| 12 hours | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No possibility of size the type of statistical analyse : the sample size was calculated using the Fleming-A'hern single-stage design²³ assuming that the proportion of patients with a 12h-VAS \geq 2p-decrease during at least two of the three consecutive days following patch application should result in at least 60%. A rate of 60% or less would mean that the benefit in pain relief is not confirmed. Assuming a 5% one-sided alpha and 85% power, 39 patients had to be enrolled. A minimum of 29 successes w

| | | | | |
|-----------------------------|-----------------|--|--|--|
| End point values | Experimental | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 39 | | | |
| Units: hours | 39 | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

The investigator collects (spontaneous patient report or questioning) and immediately notifies the sponsor of all SAEs, in a written report, whether or not they are deemed to be attributable to research and which occur during the study

Adverse event reporting additional description:

3 (7.7%, 95%CI [1.6%-20.9%]) patients experienced at least one grade 1 or 2 adverse event with only two events possibly related to the patch application (one localized erythema and one pruritus at the application site). One generalized skin eruption was recorded but assessed as unlikely related to treatment. No serious adverse event was observed.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 21.0 |
|--------------------|------|

Frequency threshold for reporting non-serious adverse events: 5 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: 3 (7.7%, 95%CI [1.6%-20.9%]) patients experienced at least one grade 1 or 2 adverse event with only two events possibly related to the patch application (one localized erythema and one pruritus at the application site). One generalized skin eruption was recorded but assessed as unlikely related to treatment. No serious adverse event was observed

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 25 November 2011 | modification of criteria inclusion + prolongation of inclusion period |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported